Saltar al contenido
Merck

V-004

Venlafaxine hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Acerca de este artículo

Fórmula empírica (notación de Hill):
C17H28ClNO2
Número CAS:
99300-78-4
Peso molecular:
313.86
NACRES:
NA.24
UNSPSC Code:
41116107
EC Number:
200-659-6

Documentos clave

Ver Toda la documentación
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

InChI key

QYRYFNHXARDNFZ-UHFFFAOYSA-N

InChI

1S/C17H27NO2.ClH/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14;/h7-10,16,19H,4-6,11-13H2,1-3H3;1H

SMILES string

Cl.COc1ccc(cc1)C(CN(C)C)C2(O)CCCCC2

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

Quality Level

300

Gene Information

human ... SLC6A2(6530), SLC6A4(6532)

Categorías relacionadas

General description

A Certified Snap-N-Spike® Solution suitable for many LC/MS and GC/MS applications from forensic or clinical toxicology analysis to urine drug testing. Also known by the brand name Effexor®, venlafaxine is an SNRI antidepressant approved for the treatment of major depressive and general anxiety disorders.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Effexor is a registered trademark of American Home Product Corp.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Clase de almacenamiento

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Depersonalization and derealization syndrome: report on a case study and pharmacological management.
Ana Salgado et al.
Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 34(4), 505-508 (2013-02-23)
M Batista et al.
Clinical toxicology (Philadelphia, Pa.), 51(2), 92-95 (2013-01-11)
Venlafaxine is a bicyclic antidepressant that may be associated with severe cardiotoxicity following large overdose. The purpose of this short case series is to present different patterns of venlafaxine-related cardiotoxicity and to discuss the potential mechanisms. Between January 2010 and
Mandar J Bhandwalkar et al.
AAPS PharmSciTech, 14(1), 101-110 (2012-12-12)
In order to improve the bioavailability of the antidepressant drug, venlafaxine hydrochloride, in situ mucoadhesive thermoreversible gel, was formulated using Lutrol F127 (18%) as a thermo gelling polymer. Mucoadhesion was modulated by trying carbopol 934, PVP K30, HPMC K4M, sodium
Krystyna Cegielska-Perun et al.
Pharmacology, 91(1-2), 69-76 (2012-11-28)
The possible mechanisms involved in the antinociceptive effect of venlafaxine (VFX), a selective serotonin and noradrenaline reuptake inhibitor, after a single administration and chronic treatment were investigated in a diabetic neuropathic pain (DNP) model. VFX produced a significant antihyperalgesic effect
Aaron S Heller et al.
The American journal of psychiatry, 170(2), 197-206 (2012-12-12)
OBJECTIVE Deficits in positive affect and their neural bases have been associated with major depression. However, whether reductions in positive affect result solely from an overall reduction in nucleus accumbens activity and fronto-striatal connectivity or the additional inability to sustain
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico